Virtual and In Vitro Bioassay Screening of Phytochemical Inhibitors from Flavonoids and Isoflavones Against Xanthine Oxidase and Cyclooxygenase-2 for Gout Treatment

Chemical Biology and Drug Design

Volumn 81, Issue 4, 2013, Pages 537-544

  Li, Yadi ^a,b   Frenz, Christopher M ^c   Li, Zhiwen ^b   Chen, Mianhua ^a   Wang, Yurong ^a   Li, Fengjuan ^a   Luo, Cheng ^a,d   Sun, Jian ^e   bohlin, Lars ^f   Li, Zhenjing ^a   Yang, Hua ^a   Wang, Changlu ^a  

^a TIANJIN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b Lunan Pharmaceutical Group Shandong New Time Pharmaceutical Co Ltd   (China)

^c NEW YORK CITY COLLEGE OF TECHNOLOGY   (United States)

^d UNIVERSITY OF TARTU   (Estonia)

^e UNIVERSITY OF HONG KONG   (Hong Kong)

^f UPPSALA UNIVERSITY   (Sweden)

Author keywords

Cycooxygenase 2; Flavonoids; Gout; Inhibitor; Multitarget therapeutics; Structure activity relationship; Xanthine oxidase

Indexed keywords

CYCLOOXYGENASE 2 INHIBITOR; FLAVONOID; ISOFLAVONE DERIVATIVE; LUTEOLIN; MYRICETIN; PLANT MEDICINAL PRODUCT; XANTHINE OXIDASE INHIBITOR;

ARTICLE; BIOASSAY; COMPUTER PROGRAM; CONTROLLED STUDY; DRUG DATABASE; DRUG SCREENING; ENZYME INHIBITION; GOUT; IC 50; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION;

BINDING SITES; BIOLOGICAL ASSAY; CYCLOOXYGENASE 2; DATABASES, CHEMICAL; DRUG DESIGN; ENZYME INHIBITORS; FLAVONOIDS; GOUT; HUMANS; ISOFLAVONES; MOLECULAR DOCKING SIMULATION; PROTEIN STRUCTURE, TERTIARY; SOFTWARE; STRUCTURE-ACTIVITY RELATIONSHIP; XANTHINE OXIDASE;

EID: 84875650768     PISSN: 17470277     EISSN: 17470285     Source Type: Journal    
DOI: 10.1111/cbdd.1248     Document Type: Article

References (30)

1. Ramoju S. (2009) Analysis of metabolic disorder-gout. MWSUG http://www.mwsug.org/proceedings/2009/pharma/MWSUG-2009-P05.pdf.
2. Choi H.K., Mount D.B., Reginato A.M. (2005) Pathogenesis of gout. Ann Intern Med;143:499-516.
3. Arromdee E., Michet C.J., Crowson C.S. (2002) Epidemiology of gout: is the incidence rising? J Rheumatol;29:2403-2406.
4. Grodzicki T., Palmer A., Bulpitt C.J. (1997) Incidence of diabetes and gout in hypertensive patients during 8years of follow up. J Hum Hypetens;11:583-585.
5. Terkeltaub R.A. (2003) Clinical practice of Gout. N Engl J Med;349:1647-1655.
6. Perez-Ruiz F., Martin I., Canteli B. (2007) Ultrasonographic measurement of tophi as an outcome measure for chronic gout. J Rheumatol;34:1888-1893.
7. Gutman A.B. (1973) The past four decades of progress in the knowledge of gout, with an assessment of the present status. Arthritis Rheum;16:43-45.
8. Perez-Ruiz F., Gomez-Ullate P., Amenabar J.J., Zarraga S., Calabozo M., Herrero Beites A.M. et al. (2003) Long-term efficacy of hyperuricaemia treatment in renal transplant patients. Nephrol Dial Transplant;18:603-606.
9. Jansen T.L., Reinders M.K., Van Roon E.N., Brouwers J.R. (2004) Benzbromarone withdrawn form the European market: another case of "absence of evidence is evidence of absence?” Clin Exp Rheumatol;22:651.
10. Harvey A. (2000) Strategies for discovering drugs from previously unexplored natural products. Drug Discov;5:294-300.
11. Lin J.K., Tsai S.H., Lin-Shiau S.Y. (2001) Antiinflammatory and antitumor effects of flavonoids and flavanoids. Drug Future;26:145-152.
12. Metodiewa D., Kochman A., Karolczak S. (1997) Evidence for antiradical and antioxidant properties of four biologically active N, N-diethylaminoethyl ethers of flavanone oximes: a comparison with natural polyphenolic flavonoid (rutin) action. Biochem Mol Biol Int;41:1067-1075.
13. Havsteen B.H. (2002) The biochemistry and medical significance of the flavonoids. Pharm Therap;96:67-202.
14. Hayashi T., Sawa K., Kawasaki M., Arisawa M., Shimizu M., Morita N. (1988) Inhibition of cow's milk xanthine oxidase by flavonoids. J Nat Prod;51:345-348.
15. Xu Y., Li X.Y. (2009) Multi-target therapeutics and new drug discovery. Acta Pharmaceutica Sinica;44:226-230.
16. Zimmermann G.R., Lehar J., Keith C.T. (2007) Multi-target therapeutics: when the whole is greater than the sum of the parts. Drug Discov Today;12:34-42.
17. Morphy R., Kay C., Rankovic Z. (2004) From magic bullets to designed multiple ligands. Drug Discov Today;9:641-651.
18. Guo Y.S., Guo Z.R. (2009) Design of multiple targeted drugs. Acta Pharmaceutica Sinica;44:276-281.
19. Pacher P., Nivorozhkin A., Szabó C. (2006) Therapeutic effects of xanthine oxidase inhibitor: renaissance a century after the discovery of allopurinol. Pharmacological Rev;58:87-114.
20. da Silva S.L., da Silva A., Honorio K.M., Marangoni S., Toyama M.H., da Silva A.B.F. (2004) The influence of electronic, steric and hydrophobic properties of flavonoid compounds in the inhibition of the xanthine oxidase. J Mol Struct (Theochem);684:1-7.
21. Kirby B.S., McTigue J.C., Edwards N.L. (2008) Pain management in gout. Curr Pain Headache Rep;12:418-422.
22. Jia S. (editor) (2006) Drug Screening In Vitro. Beijing, China: Chemical Industry Press.
23. Walters W.P., Stahl M.T., Murcko M.A. (1998) Virtual screening - an overview. Drug Discov;3:160-178.
24. Drews J.A. (2000) Historical perspective. Science;287:1960-1964.
25. Yang J.M., Chen C.C. (2004) GEMDOCK: A generic evolutionary method for molecular docking. Proteins;55:288-304.
26. Umamaheswari M., AsokKumar K. (2006) Xanthine oxidase inhibitory activity of some India medical plants. J Ethnopharmacology;10:10-16.
27. Niuchao Z.Z. (2001) The separation and identification of flavonoids from Toona sinensis. China Acad J;24:10-14.
28. Sudha K.N., Shakira M., Prasanthi P., Sarika N., Kumar Ch.N. (2008) Virtual screening for novel COX-2 inhibitors using the ZINC database. Bioinformation;13:325-329.
29. Lin C.-M., Chen C.-S., Chen C.-T. (2002) Molecular modeling of flavonoids that inhibits xanthine oxidase. Biochem Biophysl Res Commun;294:67-172.
30. Komoda F., Sekine T. (2004) The W258X mutation in SLC22A12 is the predominant cause of Japanese renal hypouricemia. Pediatr Nephrol;19:728-733.